Skip to content

Teleflex

US · TFX #2082 by market cap Listed 1970
161.58 -1.82 -1.11%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 1.76 Cheap vs history 24th percentile
5-year average 2.36 · #16 of 51 in Medical Instruments & Supplies
P/E ratio 20.41 Cheap vs history 22nd percentile
5-year average 25.32 · forward 24.39 · #7 of 27 in Medical Instruments & Supplies
P/S ratio 2.73 Cheap vs history 32nd percentile
5-year average 3.31 · forward 2.65 · #25 of 51 in Medical Instruments & Supplies

Vs. peers Medical Instruments & Supplies

Company Market cap P/E (TTM) P/B Div yield
Teleflex (TFX) 6.41B 21.26 1.83 0.84%
Intuitive Surgical (ISRG) 138.33B 48.25 8.65 0.00%
Becton Dickinson & Co (BDX) 57.96B 52.02 2.35 1.97%
Alcon (ALC) 35.92B 54.24 1.64 0.48%
ResMed (RMD) 33.14B 21.46 5.57 1.04%
Medline (MDLN) 32.55B 57.52 2.76 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value155.41 Economic moatNone UncertaintyLow

Trading 3.8% above Morningstar's fair value estimate.

Fair value

Teleflex Inc is assigned a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a price consistent with our quantitative fair value estimate, which has a low uncertainty rating.

The firm's lack of profitability decreases our valuation estimate. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. For example, the firm's enterprise value to free cash flow ratio falls in the top 1% globally. This suggests limited cash flow is available for reinvestment or return to shareholders, which contributes to our balanced fair value estimate.

The company's valuation metrics are an additional cause for concern. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's free cash flow yield of -1.5%, for example, sits in the bottom 30% compared with peers globally. Equity in this company looks expensive relative to the free cash flow it is generating. Unless cash flow increases, shares could reprice to a higher yield. This characteristic further promotes our neutral price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is fairly-valued, this outperformance had a negative impact on our valuation estimate.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Teleflex discussion 0 comments

Add a comment